Insights & news

Van Bael & Bellis adds banking, finance and projects team to its transactional services offering

  • 10/01/2022
  • News

In a move that underlines the strategic growth of its transactional services team, international independent law firm Van Bael & Bellis (VBB) is pleased to announce the arrival of leading banking, finance and projects partner Johan Mouraux alongside associate Lucas De Four.

Based in VBB’s Brussels office, Johan is a seasoned banking, finance and projects partner with two decades of experience who will add strong expertise to the wide range of transactional expertise within the firm.  Johan joins from DLA Piper[1] where he was a partner and head of the Belgium office’s finance, projects and restructuring practice group.  Johan has experience advising all parties involved in financing transactions, including arrangers, lenders, borrowers, investors, sponsors and public authorities.  Johan has particular expertise in the infrastructure sector, renewables, in real estate finance and in leveraged finance.  He also acts on debt restructuring transactions, and advises on financial services regulation in the banking, insurance, and investment services sectors.

Johan has been recognised for many years as a leading practitioner in the main legal directories such as Chambers & Partners, Legal 500 and IFLR 1000, and has received the top accolade of Global Thought Leader in project finance in the International Who’s Who Legal guide. 

Caroline and Lucas also join from DLA Piper.  Together with Johan, the team have built up a leading marketplace reputation.  Client testimonies about the team refer to “a deal-maker firm, which is absolutely primordial for us" and “close, pragmatic, very aware of the environment in which banking operates and very hands-on" (Chambers and Partners 2021), whilst Legal 500 describes the group as “an excellent team of knowledgeable, trustworthy and customer-oriented legal experts”, who are “flexible and take a pro-active approach in getting the deal through” and with “in-depth knowledge of the market”.  

About the Transactional Services Team of VBB

VBB’s transactional services team handles all ranges of complex Belgian and cross-border transactional services.  This includes mergers and acquisitions, capital markets (debt and equity), insolvency and restructuring, private equity and venture capital transactions, as well as corporate real estate transactions.  The transactional services team benefits from the firm’s expertise in other areas, including competition, employment and benefits, dispute resolution and arbitration, general commercial law, intellectual property, GDPR, as well as our sector-specific public law expertise in highly regulated markets (such as renewable energy, telecom, aviation, etc.).  

The team is consistently ranked as one of the leading independent corporate M&A practices in Belgium.

Philippe De Baere, managing partner, comments: “The arrival of Johan and his team is part of our long-standing strategy to be leaders in the specific areas we focus on.  Our transactional services team has gone from strength to strength for well over a decade now and will continue its growth in the future.  Following the opening of our London office, this move shows once again that VBB is a firm that invests in high-end expertise for its clients.

Michel Bonne, head of the transactional services team, adds: “Johan’s team adds strong expertise to our wide range of transactional services, in Belgium and abroad.  We work continuously with Belgian and multinational clients and the finest independent firms around the globe, and Johan’s expertise fits neatly into our strategic goal of being the go-to independent in the market.  We are very excited to work with Johan and his team.

 
[1] Johan joined DLA Piper in 2007 and was made partner in 2012.  He was appointed as head of the finance, projects and restructuring practice group in Belgium in 2017

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 27/06/2022
    • Articles

    Spanish Competition Authority Set to Continue Excessive Pricing Probe Against Leadiant

    On 15 June 2022, the Spanish competition authority (Comisión Nacional de los Mercados y la Competencia – CNMC) rejected the appeal by Leadiant Biosciences SpA, Leadiant Biosciences Ltd, Leadiant GmbH and Sigma Tau Arzneimittel GmbH (together, Leadiant) against the decision of the Competition Directorate of the CNMC of 3 March 2022 to discontinue the settlement negotiations with Leadiant aiming to terminate the abuse of dominance probe which the CNMC launched against Leadiant on 22 December 2020 for alleged excessive pricing of chenodeoxycholic acid (CDCA) (see, Van Bael & Bellis Life Sciences Insights and News Alert of 22 December 2020). CDCA is an orphan medicine indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare metabolic disorder. In support of its appeal, Leadiant submitted that the Competition Directorate had violated Article 47 of the Spanish competition law (Law 15/2007, 3 July 2007) by rejecting its proposed commitments and ending the settlement procedure. More precisely, Leadiant argued that the Competition Directorate had infringed its rights of defence and had caused it irreparable harm, which are two possible grounds of appeal under Article 47 of the Spanish competition law. First, regarding the alleged infringement of Leadiant’s rights of defence, the CNMC held that the Competition Directorate had, in fact, provided Leadiant with a sufficiently detailed and reasoned explanation as to why it rejected the proposed commitments. Hence, Leadiant’s rights of defence had not been violated. Second, regarding its alleged irreparable harm, Leadiant argued that this harm would result from a violation of Article 47(1)(b) and (e) of Law 30/2015, 1 October 2015, which regulates the common administrative procedures in the Spanish public sector. Pursuant to these provisions, a decision is void if it was adopted by an authority which is not competent or if the procedure followed is not the adequate one for that decision. However, the CNMC disagreed with Leadiant, holding that the Competition Directorate was competent and had complied with all applicable legal requirements. Consequently, the CNMC concluded that the Competition Directorate’s decision was not void, had not ignored Leadiant’s right of defence and had not caused irreparable harm. This implies that the CNMC will continue its excessive pricing probe against Leadiant. A final decision is expected before August 2023. Leadiant’s pricing practices have already been fined in the Netherlands (see, Van Bael & Bellis Life Sciences Insights and News Alert of 20 July 2021) and Italy (see, Van Bael & Bellis Life Sciences Insights and News Alert of 1 June 2022), whilst they are being investigated in other Member States including Belgium (see, Van Bael & Bellis Life Sciences Insights and News Alert of 9 September 2019).

    Read more
    • 23/06/2022
    • Articles

    Belgian Government Think-Tank Publishes Study on Compulsory Licensing for Expensive Medicines

    On 14 June 2022, the Belgian Health Care Knowledge Centre (KCE), a research institute funded by the federal government, published a study discussing “Compulsory Licensing for Expensive Medicines” (the CL Study). The CL Study was commissioned by the Committee for Health and Equal Opportunities of the federal Chamber of Representatives which is reviewing bill 55K407 that seeks to expand the existing system of compulsory licensing for patented medicinal products in the interest of public health (Article XI.38(1) Code of Economic Law). The publication of the CL Study preceded by a few days the adoption of an intellectual property waiver for Covid-19 vaccines by the Twelfth Ministerial Conference of the World Trade Organisation (see, Van Bael & Bellis Life Sciences News and Insights of 20 June 2022) and was almost immediately welcomed in Parliament by the Minister of Social Affairs and Public Health. While the compulsory licensing of pharmaceutical patents is therefore clearly a trending topic, the CL Study is strikingly cautious in making policy recommendations. This is because compulsory licensing for expensive medicines not only raises questions of principle but also of practical implementation. Additionally, high medicine prices are generally the result of increasingly complex technological innovations. The CL Study therefore advocates a comprehensive approach that considers the entire regulatory framework, not just patent law, and is in favour of calibrated measures that do not jeopardise the benefits of the current system which seeks to encourage and reward innovation. That is a crucial concern for a country such as Belgium which hosts a thriving ecosystem of pharmaceutical and biotechnological research, development, clinical trials and production facilities. Additionally, the incentives for innovation encompass a range of measures covering patent law, know-how, data and market exclusivity, and targeted rules that stimulate the development of orphan and paediatric medicines. Lastly, the CL Study fully recognises the difficulties associated with defining an excessive price for medicines. It notes that the excessive pricing cases brought by European competition authorities all involve off-patent medicines (for a recent example with regard to Leadiant, see, Van Bael & Bellis Life Sciences News and Insights of 1 June 2022). On this basis, the CL study makes the following policy recommendations: • Compulsory licensing should not be an end, but rather a means to bring down prices in exceptional circumstances. • EU Member States should coordinate any initiatives to impose compulsory licensing in specific cases. • Adaptations to the current rules governing exclusivity and data access could be envisaged but require careful consideration. • In Belgium, the exchange of expertise between pricing and reimbursement authorities and the Belgian Competition Authority should be improved. • There is always scope for a more robust pricing and reimbursement policy and increased cooperation at EU and international level. • The patent exemption for pharmacists should be optimised. • Universities and public research institutions should apply “socially responsible licensing conditions”. • Collaborative models for patent licensing should be encouraged.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *